Company Overview of Calypte Biomedical Corp.
Calypte Biomedical Corporation develops, manufactures, and distributes in vitro diagnostic tests primarily for the diagnosis of human immunodeficiency virus (HIV) infection. The company focuses on the commercialization of HIV-1/2 rapid test products for the rapid detection of antibodies to HIV-1 and HIV Type 2 in oral fluid using a lateral flow dipstick design. Its products also comprise Aware HIV-1/2 OMT test to address the drawbacks of blood testing; and Aware HIV-1/2 Oral OTC test, which is an over-the-counter version of oral fluid rapid test. In addition, the company provides Aware BED HIV-1 Incidence Test that is used to estimate the rate of new HIV infections in a population by determi...
15875 SW 72nd Avenue
Portland, OR 97224
Founded in 1988
Key Executives for Calypte Biomedical Corp.
Chairman, Chief Executive Officer, President and Member of Nominating Committee
Chief Financial Officer, Principal Accounting Officer, Vice President, Secretary and Director
President of Geneva Branch Office
Vice President of Sales and Marketing
Compensation as of Fiscal Year 2015.
Calypte Biomedical Corp. Key Developments
SEC Revokes Registration Of Securities Of Calypte Biomedical Corporation For Failure To Make Required Periodic Filings
Apr 6 15
Securities and Exchange Commission (SEC or the commission) revoked the registration of each class of the registered securities of Calypte Biomedical Corporation for failure to make required periodic filings with the Commission. SEC reported that the company failed to comply with Section 13(a) of the Securities Exchange Act of 1934 (Exchange Act) and Rules 13a-1 and 13a-13 there under and revoking the registration of each class of the company’s securities pursuant to Section 12(j) of the Exchange Act.
SEC Orders Hearings On Registration Suspension Or Revocation Against Calypte Biomedical Corporation For Failure To Make Required Periodic Filings
Feb 20 15
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Calypte Biomedical Corporation for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Calypte Biomedical Corp. Auditor Raises 'Going Concern' Doubt
Jun 24 14
Calypte Biomedical Corp. filed its 10-K on Jun 24, 2014 for the period ending Dec 31, 2012. In this report its auditor, Odenberg Ullakko Muranishi & Co LLP - OUM & Co LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries